CUMULATIVE SUPPLEMENT 4
April 2011



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Cumulative Supplement 4

April 2011

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

CUMULATIVE SUPPLEMENT 4
April 2011

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2010	MAR 2011	JUN 2011	SEPT 2011	DEC 2011
DRUG PRODUCTS LISTED	13838	14029			
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)			
MULTISOURCE	11267 (81.4%)	11463 (81.7%)			
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)			
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)			
EXCEPTIONS[1]	89 (0.6%)	89 (0.6%)			
NEW MOLECULAR ENTITIES APPROVED	8	6			
NUMBER OF APPLICANTS	752	768			

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

>A>		ABIRATERONE ACETATE							
>A>		TABLET; ORAL							
>A>		ZYTIGA							
>A>	+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Apr	NEWA	
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE							
		TABLET; ORAL							
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
AA		MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN	
AA			500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN	
		ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE							
		CAPSULE; ORAL							
		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE							
AA		WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN	
		ACETAMINOPHEN; HYDROCODONE BITARTRATE							
		TABLET; ORAL							
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
AA		BOCA PHARMA	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC	
AB			300MG;5MG	A090415	001	Jan 24, 2011	Jan	NEWA	
AA			300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC	
AB			300MG;7.5MG	A090415	002	Jan 24, 2011	Jan	NEWA	
AA			300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC	
AB			300MG;10MG	A090415	003	Jan 24, 2011	Jan	NEWA	
AA	+	MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Mar	CRLD	
AA			300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC	
AA	+		300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC	
AA	+		300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC	
		LORTAB							
AA		UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN	
		ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE							
		TABLET; ORAL							
		PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN							
		@ VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003	Mar	DISC	
		ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE							
		TABLET; ORAL							
		DARVOCET-N 100							
		@ XANODYNE PHARM	650MG;100MG	N017122	002		Jan	DISC	
		DARVOCET-N 50							
		@ XANODYNE PHARM	325MG;50MG	N017122	001		Jan	DISC	
		PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN							
		@ CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004	Mar	DISC	
		@	500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC	
>D>	AB	MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC	
>A>		@	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC	
	AB		650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN	
		@ TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC	
		@ VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC	
		@	650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC	

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB		MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN

TABLET; ORAL
ACYCLOVIR

AB		MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
AB			800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

		@ HOSPIRA	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL
ACLOVATE

AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Mar	CAHN

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

AB		MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
AB			EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
		@ SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
		@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
		@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
		@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC
		@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB		IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
AB			300MG	A090637	002	Mar 16, 2011	Feb	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

>A>	AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552	001	Apr 08, 2009	Apr	CAHN
>A>	AB		EQ 5MG BASE	A078552	002	Apr 08, 2009	Apr	CAHN
>A>	AB		EQ 10MG BASE	A078552	003	Apr 08, 2009	Apr	CAHN
>D>	AB	GLENMARK GENERICS	EQ 2.5MG BASE	A078552	001	Apr 08, 2009	Apr	CAHN
>D>	AB		EQ 5MG BASE	A078552	002	Apr 08, 2009	Apr	CAHN
>D>	AB		EQ 10MG BASE	A078552	003	Apr 08, 2009	Apr	CAHN
	AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011	Mar	NEWA
	AB		EQ 5MG BASE	A077771	002	Apr 12, 2011	Mar	NEWA
	AB		EQ 10MG BASE	A077771	003	Apr 12, 2011	Mar	NEWA
>A>	AB	SECAN PHARMS	EQ 5MG BASE	A090752	001	Apr 15, 2011	Apr	NEWA
>A>	AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
LOTREL

AB		NOVARTIS	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	Jan	CFTG

CAPSULE; ORAL
LOTREL

AB	+	NOVARTIS	EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB		AM ANTIBIOTICS	250MG	A062058	001		Feb	CDFR
AB			500MG	A062058	002		Feb	CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

	+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Feb	NEWA

>A> AMPICILLIN SODIUM; SULBACTAM SODIUM

>A> INJECTABLE; INJECTION
>A> AMPICILLIN AND SULBACTAM

>A> AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010	Apr	CAIN
>A> AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	Apr	CAIN
>A> AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Apr	CAIN
>A> AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Apr	CAIN
>A> AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010	Apr	CAIN

>D> AMPICILLIN; SULBACTAM

>D> INJECTABLE; INJECTION
>D> AMPICILLIN AND SULBACTAM

>D> AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010	Apr	CAIN
>D> AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	Apr	CAIN
>D> AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Apr	CAIN
>D> AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Apr	CAIN
>D> AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010	Apr	CAIN

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL
CARISOPRODOL AND ASPIRIN

AB		MIRROR PHARMS	325MG;200MG	A040832	001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA		COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Feb	NEWA
AA		WATSON LABS	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	NEWA

PERCODAN

AA	+	ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB		MYLAN	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
AB			50MG	A074126	001	Mar 23, 1994	Feb	CAHN
AB			100MG	A074126	002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	250MG;100MG	A091211	001	Jan 12, 2011	Jan	NEWA

MALARONE

AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

		TAKEDA PHARMS	40MG	N200796	001	Feb 25, 2011	Feb	NEWA
	+		80MG	N200796	002	Feb 25, 2011	Feb	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP		BEDFORD	1GM/VIAL	A065286	001	Mar 23, 2011	Mar	NEWA
AP			2GM/VIAL	A065286	002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

	+	FERA PHARMS	500 UNITS/GM	A061212	001		Feb	CAHN
	+	NYCOMED US	500 UNITS/GM	A061212	001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
AT		NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
AT		NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
	+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP		CNS THERAPS INC	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
AP			2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB		PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB			20MG	A077088	001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	5MG;6.25MG	A076612	001	Feb 11, 2004	Feb	CAHN
AB			10MG;12.5MG	A076612	002	Feb 11, 2004	Feb	CAHN
AB			20MG;12.5MG	A076612	003	Feb 11, 2004	Feb	CAHN
AB			20MG;25MG	A076612	004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	CAHN

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

>D>	AB	STAT TRADE	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Apr	CAHN
>A>	AB	STI PHARMA LLC	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Apr	CAHN

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB		ROXANE	50MG	A078285	001	Mar 24, 2011	Mar	NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

	+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD

>A> BROMFENAC SODIUM

>A>		COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	Apr	NEWA

XIBROM

	@	ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT		G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011	Mar	NEWA

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

>A>	+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581	001	Apr 18, 2011	Apr	NEWA

TABLET; ORAL

CALCIUM ACETATE

AB		PADDOCK LABS	EQ 169MG CALCIUM	A091561	001	Apr 13, 2011	Mar	NEWA

ELIPHOS

AB	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

	@	JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988	Jan	CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB		MERCK SHARP DOHME	10MG;100MG	N017555	001		Jan	CAHN
AB			25MG;100MG	N017555	003		Jan	CAHN
AB	+		25MG;250MG	N017555	002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB		MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	CAHN
AB	+		50MG;200MG	N019856	001	May 30, 1991	Jan	CAHN

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA		MIRROR PHARMS	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
AA		PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL
CEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462	002	May 28, 2008	Jan	CRLD
	VANTIN						
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Jan	DISC
	@	EQ 200MG BASE	N050674	002	Aug 07, 1992	Jan	DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION
CEFTRIAXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168	001	May 17, 2005	Jan	CRLD

CEFUROXIME SODIUM

INJECTABLE; IM-IV
CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL
CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117	001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117	002		Jan	CAHN

FOR SUSPENSION; ORAL
CEPHALEXIN

AB	+	ACS DOBFAR	EQ 250MG BASE/5ML	A062117	003			Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT		LYNE	0.12%	A074291	001	Dec 28, 1995		Feb	CAHN

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA		NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011		Jan	NEWA
AA			EQ 300MG BASE	A090612	001	Jan 21, 2011		Jan	NEWA

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

>D>	AB		SANDOZ	EQ 4GM RESIN/PACKET	A074557	001	Aug 15, 1996	Apr	CRLD
>A>	AB	+		EQ 4GM RESIN/PACKET	A074557	001	Aug 15, 1996	Apr	CRLD
			CHOLESTYRAMINE LIGHT						
>D>	AB		SANDOZ	EQ 4GM RESIN/PACKET	A074558	001	Aug 15, 1996	Apr	CRLD
>A>	AB	+		EQ 4GM RESIN/PACKET	A074558	001	Aug 15, 1996	Apr	CRLD
			QUESTRAN						
>D>	AB	+	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640	001		Apr	DISC
>D>	AB			EQ 4GM RESIN/SCOOPFUL	N016640	003		Apr	DISC
>A>		@		EQ 4GM RESIN/PACKET	N016640	001		Apr	DISC
>A>		@		EQ 4GM RESIN/SCOOPFUL	N016640	003		Apr	DISC
			QUESTRAN LIGHT						
>D>	AB	+	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Apr	DISC
>D>	AB			EQ 4GM RESIN/SCOOPFUL	N019669	003	Dec 05, 1988	Apr	DISC
>A>		@		EQ 4GM RESIN/SCOOPFUL	N019669	003	Dec 05, 1988	Apr	DISC
>A>		@		EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Apr	DISC
	AB	+		EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL
CICLOPIROX

AT		TARO	1%	A090269	001	Feb 23, 2011		Feb	NEWA

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

>D>	AB		MATRIX LABS INC	EQ 10MG BASE	A077042	001	Nov 05, 2004	Apr	CAHN
>D>	AB			EQ 20MG BASE	A077042	002	Nov 05, 2004	Apr	CAHN
>D>	AB			EQ 40MG BASE	A077042	003	Nov 05, 2004	Apr	CAHN
>A>	AB		MYLAN	EQ 10MG BASE	A077042	001	Nov 05, 2004	Apr	CAHN
>A>	AB			EQ 20MG BASE	A077042	002	Nov 05, 2004	Apr	CAHN
>A>	AB			EQ 40MG BASE	A077042	003	Nov 05, 2004	Apr	CAHN

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLINDAGEL

BT	+	GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000		Mar	CRLD

		SOLUTION; TOPICAL							
		CLINDAMYCIN PHOSPHATE							
>A>		@ COREPHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Apr	CAHN	
>D>		@ STIEFEL GSK	EQ 1% BASE	A064108	001	Sep 27, 1996	Apr	CAHN	
		CLOBETASOL PROPIONATE							
		CREAM; TOPICAL							
		CLOBETASOL PROPIONATE							
>A>		@ COREPHARMA	0.05%	A075338	001	Feb 09, 2001	Apr	CAHN	
>D>		@ STIEFEL	0.05%	A075338	001	Feb 09, 2001	Apr	CAHN	
		CLOBETASOL PROPIONATE (EMOLLIENT)							
>A>		@ COREPHARMA	0.05%	A075733	001	Aug 22, 2001	Apr	CAHN	
>D>		@ STIEFEL GSK	0.05%	A075733	001	Aug 22, 2001	Apr	CAHN	
		OINTMENT; TOPICAL							
		CLOBETASOL PROPIONATE							
>A>		@ COREPHARMA	0.05%	A075057	001	Aug 12, 1998	Apr	CAHN	
>D>		@ STIEFEL GSK	0.05%	A075057	001	Aug 12, 1998	Apr	CAHN	
		SOLUTION; TOPICAL							
		CLOBETASOL PROPIONATE							
>D>	AT	ALTANA	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN	
>A>	AT	NYCOMED US	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN	
		CLONIDINE HYDROCHLORIDE							
		INJECTABLE; INJECTION							
		CLONIDINE HYDROCHLORIDE							
	AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA	
	AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA	
		COLCHICINE; PROBENECID							
		TABLET; ORAL							
		PROBENECID AND COLCHICINE							
	AB	MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN	
		CYCLOBENZAPRINE HYDROCHLORIDE							
		CAPSULE, EXTENDED RELEASE; ORAL							
		AMRIX							
>D>		ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG	
>A>	AB		15MG	N021777	001	Feb 01, 2007	Apr	CFTG	
>D>	+		30MG	N021777	002	Feb 01, 2007	Apr	CFTG	
>A>	AB +		30MG	N021777	002	Feb 01, 2007	Apr	CFTG	
>A>		CYCLOBENZAPRINE HYDROCHLORIDE							
>A>	AB	MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA	
>A>	AB		30MG	A090738	002	Apr 18, 2011	Apr	NEWA	
		TABLET; ORAL							
		CYCLOBENZAPRINE HYDROCHLORIDE							
	AB	JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN	
	AB		10MG	A077563	002	Apr 19, 2006	Jan	CAHN	
	AB	KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA	
	AB		10MG	A078048	002	Feb 28, 2011	Feb	NEWA	
	AB	PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN	
	AB		10MG	A077209	001	Oct 04, 2005	Feb	CAHN	
		DESLORATADINE							
		TABLET; ORAL							
		DESLORATADINE							
	AB	DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA	

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

>D>		+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG
>A>	AB	+		5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

>A>	AB		DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011	Apr	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

	AB		VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

	AB		VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

>A>	AA		VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

	AT		FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
	AT		NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	AA		AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan	NEWA

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>D>	AB		BIOVAIL	100MG	A075492	001	Feb 11, 2000	Apr	CAHN
>A>	AB		VALEANT INTL	100MG	A075492	001	Feb 11, 2000	Apr	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>D>	AB3		BIOVAIL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
>D>	AB3			180MG	A075116	002	Dec 23, 1999	Apr	CAHN
>D>	AB3			240MG	A075116	003	Dec 23, 1999	Apr	CAHN
>D>	AB3			300MG	A075116	004	Dec 23, 1999	Apr	CAHN
>A>	AB3		VALEANT INTL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
>A>	AB3			180MG	A075116	002	Dec 23, 1999	Apr	CAHN
>A>	AB3			240MG	A075116	003	Dec 23, 1999	Apr	CAHN
>A>	AB3			300MG	A075116	004	Dec 23, 1999	Apr	CAHN

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
AB			50MG	A040542	002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

AB		ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar	CTEC
AB	+		500MG	A088483	001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB		SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar	NEWA
AB			500MG	A091619	002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB		MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

>A>	AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554	001	Apr 21, 2011	Apr	NEWA
>A>	AB		EQ 250MG VALPROIC ACID	A090554	002	Apr 21, 2011	Apr	NEWA
>A>	AB		EQ 500MG VALPROIC ACID	A090554	003	Apr 21, 2011	Apr	NEWA
	AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011	Mar	NEWA
	AB		EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011	Mar	NEWA
	AB		EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011	Mar	NEWA
	AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Mar	NEWA
	+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Mar	NEWA
	+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Mar	NEWA

TAXOTERE

	@	SANOFI AVENTIS US	40MG/ML	N020449	001	May 14, 1996	Mar	DISC

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	SANDOZ	5MG	A091198	001	May 10, 2011	Apr	NEWA
>A>	AB		10MG	A091198	002	May 10, 2011	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011	Apr	NEWA
>A>	AB		10MG	A090175	002	May 10, 2011	Apr	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB		IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
AB		MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
AB	+	PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
AB	+		EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

LORYNA

AB		SANDOZ	3MG;0.02MG	A079221	001	Mar 28, 2011	Mar	NEWA

TABLET; ORAL-28

SYEDA

AB		SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Mar	NEWA

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

		SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Feb	CFTG

EPINASTINE HYDROCHLORIDE

AT		CYPRESS PHARM	0.05%	A090870	001	Mar 14, 2011	Feb	NEWA

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

>A>	AP	MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Apr	NEWA
>A>	AP		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Apr	NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan	CAHN

GEL; TOPICAL

E-GLADES

>A>	AT	COREPHARMA	2%	A065009	001	Mar 18, 2002	Apr	CAHN
>D>	AT	STIEFEL LABS INC	2%	A065009	001	Mar 18, 2002	Apr	CAHN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN
AT	+	NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Jan	CAHN

SOLUTION; TOPICAL

ERYDERM

		@ ARBOR PHARMS INC	2%	A062290	001		Jan	CAHN

ERYTHROMYCIN

>A>		@ COREPHARMA	2%	A064127	001	Feb 14, 1997	Apr	CAHN
>D>		@ STIEFEL	2%	A064127	001	Feb 14, 1997	Apr	CAHN

SWAB; TOPICAL

ERYTHROMYCIN

>A>		@ COREPHARMA	2%	A064128	001	Jul 03, 1996	Apr	CAHN
>D>		@ STIEFEL	2%	A064128	001	Jul 03, 1996	Apr	CAHN

TABLET; ORAL

ERYTHROMYCIN

		ARBOR PHARMS INC	250MG	A061621	001		Jan	CAHN
	+		500MG	A061621	002		Jan	CAHN

TABLET, COATED PARTICLES; ORAL

PCE

		ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan	CAHN

	TABLET, COATED PARTICLES; ORAL							
	PCE							
+	ARBOR PHARMS INC	500MG	N050611	002	Aug 22, 1990	Jan	CAHN	
	TABLET, DELAYED RELEASE; ORAL							
	E-MYCIN							
	@ ARBOR PHARMS INC	250MG	A060272	001		Jan	CAHN	
	@	333MG	A060272	002		Jan	CAHN	
	ERY-TAB							
+	ARBOR PHARMS INC	250MG	A062298	001		Jan	CAHN	
+		333MG	A062298	003	Mar 29, 1982	Jan	CAHN	
+		500MG	A062298	002		Jan	CAHN	
	ERYTHROMYCIN ETHYLSUCCINATE							
	GRANULE; ORAL							
	E.E.S.							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	001		Jan	CAHN	
	ERYPED							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Jan	CAHN	
+		EQ 400MG BASE/5ML	N050207	002		Jan	CAHN	
	SUSPENSION; ORAL							
	E.E.S. 200							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639	001		Jan	CAHN	
	E.E.S. 400							
AB +	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639	002		Jan	CAHN	
	PEDIAMYCIN							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304	001		Jan	CAHN	
	PEDIAMYCIN 400							
AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304	002		Jan	CAHN	
	TABLET; ORAL							
	E.E.S. 400							
	@ ARBOR PHARMS INC	EQ 400MG BASE	A061905	001		Jan	CAHN	
BX +		EQ 400MG BASE	A061905	002	Aug 12, 1982	Jan	CAHN	
	ERYTHROMYCIN ETHYLSUCCINATE							
BX +	ARBOR PHARMS INC	EQ 400MG BASE	A061904	001		Jan	CAHN	
	TABLET, CHEWABLE; ORAL							
	E.E.S.							
	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	002		Jan	CAHN	
	ERYPED							
	@ ARBOR PHARMS INC	EQ 200MG BASE	N050297	003	Jul 05, 1988	Jan	CAHN	
	ERYTHROMYCIN STEARATE							
	TABLET; ORAL							
	ERYTHROCIN STEARATE							
	@ ARBOR PHARMS INC	EQ 125MG BASE	A060359	002		Jan	CAHN	
		EQ 250MG BASE	A060359	001		Jan	CAHN	
+		EQ 500MG BASE	A060359	003		Jan	CAHN	
	ESTRADIOL; NORETHINDRONE ACETATE							
	TABLET; ORAL							
	ACTIVELLA							
AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907	002	Dec 28, 2006	Mar	CTEC	
	ESTRADIOL AND NORETHINDRONE ACETATE							
AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324	002	Apr 04, 2011	Mar	NEWA	

ESTROPIPATE

>D>		CREAM; VAGINAL							
>D>		OGEN							
>D>	+	PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001			Apr	DISC
>A>		@	1.5MG/GM	A084710	001			Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

		TABLET; ORAL-28							
>A>		ORSYTHIA							
>A>	AB1	VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011		Apr	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

		TABLET; ORAL-28							
		BRIELLYN							
	AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011		Mar	NEWA
		TABLET, CHEWABLE; ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	+	WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010		Jan	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

		TABLET; ORAL-28							
		GILDESS FE 1.5/30							
	AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005		Jan	CTNA
		GILDESS FE 1/20							
	AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005		Jan	CTNA

ETHINYL ESTRADIOL; NORGESTIMATE

		TABLET; ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011		Feb	NEWA

ETODOLAC

		CAPSULE; ORAL							
		ETODOLAC							
		@ MYLAN	200MG	A075071	001	Sep 30, 1998		Feb	CAHN
		@	300MG	A075071	002	Sep 30, 1998		Feb	CAHN
		TABLET; ORAL							
		ETODOLAC							
		@ MYLAN	400MG	A075012	001	Sep 30, 1998		Feb	CAHN
		@	500MG	A075012	002	Sep 30, 1998		Feb	CAHN

ETRAVIRINE

		TABLET; ORAL							
		INTELENCE							
		TIBOTEC	100MG	N022187	001	Jan 18, 2008		Jan	CRLD
	+		200MG	N022187	002	Dec 22, 2010		Jan	NEWA

EXEMESTANE

		TABLET; ORAL							
		AROMASIN							
	AB +	PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999		Mar	CFTG
		EXEMESTANE							
	AB	ROXANE	25MG	A077431	001	Apr 01, 2011		Mar	NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	AUROBINDO PHARMA LTD	125MG	A091114	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A091114	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A091114	003	Mar 21, 2011	Mar	NEWA
AB	MYLAN	125MG	A201333	001	Mar 24, 2011	Mar	NEWA
AB		250MG	A201333	002	Mar 24, 2011	Mar	NEWA
AB		500MG	A201333	003	Mar 24, 2011	Mar	NEWA
AB	ROXANE	125MG	A090128	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A090128	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A090128	003	Mar 21, 2011	Mar	NEWA
AB	WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A078278	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A078278	003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

PEPCID

@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE

@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan	DISC

TABLET; ORAL

FAMOTIDINE

AB	MYLAN	20MG	A075457	001	Apr 18, 2001	Feb	CAHN
AB		40MG	A075457	002	Apr 18, 2001	Feb	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

>A>	+	HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011	Apr	NEWA

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

	SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
	+	120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan	NEWA

FENTANYL-25

AB	MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan	NEWA

FENTANYL-50

AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan	NEWA

FENTANYL-75

AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

TABLET; SUBLINGUAL

ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA

TABLET; SUBLINGUAL
ABSTRAL

		PROSTRAKAN INC	EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA
			EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Jan	NEWA
	+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Jan	NEWA
			EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Jan	NEWA
			EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

		DR REDDYS LABS LTD	180MG;240MG	A079043	001	Mar 17, 2010	Jan	CTEC

FLUCONAZOLE

TABLET; ORAL
FLUCONAZOLE

AB		AMNEAL PHARM	50MG	A078423	001	Mar 07, 2011	Feb	NEWA
AB			100MG	A078423	002	Mar 07, 2011	Feb	NEWA
AB			150MG	A078423	003	Mar 07, 2011	Feb	NEWA
AB			200MG	A078423	004	Mar 07, 2011	Feb	NEWA
AB		MYLAN	50MG	A076042	001	Jul 29, 2004	Feb	CAHN
AB			100MG	A076042	002	Jul 29, 2004	Feb	CAHN
AB			150MG	A076042	003	Jul 29, 2004	Feb	CAHN
AB			200MG	A076042	004	Jul 29, 2004	Feb	CAHN

FLUDARABINE PHOSPHATE

TABLET; ORAL
OFORTA

>D>		@ SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	Apr	CMFD
>A>		+	10MG	N022273	001	Dec 18, 2008	Apr	CMFD
		@	10MG	N022273	001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	+	FEINSTEIN	20-200mCi/ML	N021870	001	Aug 19, 2005	Feb	CTEC
AP		PETNET	20-200mCi/ML	A079086	001	Feb 25, 2011	Feb	NEWA

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

>A>	AP	SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011	Apr	NEWA
>A>	AP		5GM/100ML (50MG/ML)	A091299	002	May 02, 2011	Apr	NEWA
		@ VALEANT	500MG/10ML (50MG/ML)	N012209	001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

>D>	AB1	ALEMBIC LTD	EQ 10MG BASE	A090223	001	Mar 19, 2009	Apr	CAHN
>D>	AB1		EQ 20MG BASE	A090223	002	Mar 19, 2009	Apr	CAHN
>D>	AB		EQ 40MG BASE	A090223	003	Mar 19, 2009	Apr	CAHN
>A>	AB1	ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223	001	Mar 19, 2009	Apr	CAHN
>A>	AB1		EQ 20MG BASE	A090223	002	Mar 19, 2009	Apr	CAHN
>A>	AB		EQ 40MG BASE	A090223	003	Mar 19, 2009	Apr	CAHN

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE

AB		MYLAN	125MG	A076224	001	May 09, 2003	Feb	CAHN

FLUTICASONE PROPIONATE

LOTION; TOPICAL
CUTIVATE

>D>		+ NYCOMED US	0.05%	N021152	001	Mar 31, 2005	Apr	CFTG
>A>	AB	+	0.05%	N021152	001	Mar 31, 2005	Apr	CFTG

>A> FLUTICASONE PROPIONATE

>A>	AB	GLENMARK GENERICS	0.05%	A090759	001	May 02, 2011	Apr	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

		@ MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
		@	100MG	A075950	002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL
FOLIC ACID

>A>	AA	+ AMNEAL PHARM	1MG	A040625	001	Jul 21, 2005	Apr	CAHN
	AA	JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN
>D>	AA	+ PHARMAX	1MG	A040625	001	Jul 21, 2005	Apr	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL
FOSINOPRIL SODIUM

	AB	AUROBINDO PHARMA LTD	10MG	A091163	001	Mar 30, 2011	Mar	NEWA
	AB		20MG	A091163	002	Mar 30, 2011	Mar	NEWA
	AB		40MG	A091163	003	Mar 30, 2011	Mar	NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

>D>	AP	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Apr	CRLD
>A>	AP	+	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Apr	CRLD

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

	AB	MATRIX LABS LTD	100MG	A090158	001	Feb 14, 2011	Jan	NEWA
	AB		300MG	A090158	002	Feb 14, 2011	Jan	NEWA
	AB		400MG	A090158	003	Feb 14, 2011	Jan	NEWA

SOLUTION; ORAL
GABAPENTIN

	AA	HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011	Feb	NEWA

NEURONTIN

	AA	+ PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL
GABAPENTIN

	AB	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan	NEWA
	AB		800MG	A078926	002	Feb 11, 2011	Jan	NEWA

TABLET; ORAL
GRALISE

BX	+	ABBOTT PRODS	300MG	N022544	001	Jan 28, 2011	Jan	NEWA
BX	+		600MG	N022544	002	Jan 28, 2011	Jan	NEWA

>A> GABAPENTIN ENACARBIL

>A> TABLET, EXTENDED RELEASE; ORAL
>A> HORIZANT

>A>	+	GLAXO GRP LTD	600MG	N022399	001	Apr 06, 2011	Apr	NEWA

GADOBUTROL

SOLUTION; INTRAVENOUS
GADAVIST

	+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011	Mar	NEWA
	+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011	Mar	NEWA
	+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011	Mar	NEWA
	+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011	Mar	NEWA
	+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL
GALANTAMINE HYDROBROMIDE

AB		MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090900	002	Jan 24, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090900	003	Jan 24, 2011	Jan	NEWA
AB		SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090178	002	Feb 02, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090178	003	Feb 02, 2011	Jan	NEWA

TABLET; ORAL
GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar	NEWA
AB			EQ 8MG BASE	A090957	002	Mar 29, 2011	Mar	NEWA
AB			EQ 12MG BASE	A090957	003	Mar 29, 2011	Mar	NEWA
AB		ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan	NEWA
AB			EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan	NEWA
AB			EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE

	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD

GEMCITABINE HYDROCHLORIDE

AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT	NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB		2MG	A077486	002	Feb 10, 2006	Feb	CAHN
AB		4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB		2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB		5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB	INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA
AB		2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA
AB		5MG	A090937	003	Feb 28, 2011	Feb	NEWA

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ ELORAC	125MG	A061996	001			Jan	CAHN
@	250MG	A061996	002			Jan	CAHN

FULVICIN P/G 165

@ ELORAC	165MG	A061996	003	Apr 06, 1982	Jan	CAHN

FULVICIN P/G 330

@ ELORAC	330MG	A061996	004	Apr 06, 1982	Jan	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

>A>	AB	NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Apr	NEWA

TUSSIGON

>D>		+ KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Apr	CTEC
>A>	AB	+	1.5MG;5MG	A088508	001	Jul 30, 1985	Apr	CTEC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	ALEMBIC LTD	12.5MG	A200645	001	Nov 30, 2010	Apr	CAHN
>A>	AB	ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010	Apr	CAHN
	AB	JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Jan	CAHN
AB		50MG	A040809	002	Sep 04, 2007	Jan	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180	002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180	003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A> AB	INVAGEN PHARMS	12.5MG;10MG	A201356	001	Apr 20, 2011	Apr	NEWA
>A> AB		12.5MG;20MG	A201356	002	Apr 20, 2011	Apr	NEWA
>A> AB		25MG;20MG	A201356	003	Apr 20, 2011	Apr	NEWA

HYDROCORTISONE

TABLET; ORAL
HYDROCORTISONE

>A> AB	COREPHARMA	5MG	A040646	001	Mar 30, 2007	Apr	CAHN
>A> AB		10MG	A040646	002	Mar 30, 2007	Apr	CAHN
>A> AB		20MG	A040646	003	Mar 30, 2007	Apr	CAHN
>D> AB	STIEFEL GSK	5MG	A040646	001	Mar 30, 2007	Apr	CAHN
>D> AB		10MG	A040646	002	Mar 30, 2007	Apr	CAHN
>D> AB		20MG	A040646	003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC
HYDROCORTISONE ACETATE

@ FERA PHARMS	0.5%	A080828	001		Mar	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL
HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005	Feb	CAHN

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

>D>	CYANOKIT							
>A>	@ MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREDRINE

@ PHARMICS	1%	N000004	004		Jan	CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR
MAKENA

+	KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Feb	NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HYDROCHLORIDE

AP	SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Mar	NEWA

ILOPERIDONE

TABLET; ORAL
FANAPT

	NOVARTIS	2MG	N022192	002	May 06, 2009	Jan	CAHN
		4MG	N022192	003	May 06, 2009	Jan	CAHN
		6MG	N022192	004	May 06, 2009	Jan	CAHN
		8MG	N022192	005	May 06, 2009	Jan	CAHN
		10MG	N022192	006	May 06, 2009	Jan	CAHN

IMIQUIMOD

CREAM; TOPICAL
IMIQUIMOD

>A> AB	TARO	5%	A200173	001	Apr 15, 2011	Apr	NEWA
>A> AB	TEVA PHARMS USA	5%	A200481	001	Apr 18, 2011	Apr	NEWA
AB	TOLMAR	5%	A091044	001	Feb 28, 2011	Feb	NEWA

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

AB +	SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA

IOFLUPANE I-123

SOLUTION; INTRAVENOUS
DATSCAN

+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-200

	@ HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-200 IN PLASTIC CONTAINER

	@ HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250

	@ HOSPIRA	51%	A074898	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250 IN PLASTIC CONTAINER

	@ HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300

	@ HOSPIRA	61%	A074898	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300 IN PLASTIC CONTAINER

	@ HOSPIRA	61%	A074636	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370

	@ HOSPIRA	76%	A074898	004	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370 IN PLASTIC CONTAINER

	@ HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

>D>		@ LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr	CMFD
>A>			EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr	CMFD

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Feb	CAHN
AB			5MG	A077169	002	Apr 24, 2006	Feb	CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB		ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Mar	NEWA
AB			100MG	A078669	002	Apr 08, 2011	Mar	NEWA
AB			150MG	A078669	003	Apr 08, 2011	Mar	NEWA
AB			200MG	A078669	004	Apr 08, 2011	Mar	NEWA
>D>	AB	ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Apr	CAHN
	AB		25MG	A090607	001	Jan 13, 2011	Jan	NEWA
>D>	AB		100MG	A090607	002	Jan 13, 2011	Apr	CAHN
	AB		100MG	A090607	002	Jan 13, 2011	Jan	NEWA
>D>	AB		150MG	A090607	003	Jan 13, 2011	Apr	CAHN
	AB		150MG	A090607	003	Jan 13, 2011	Jan	NEWA
>D>	AB		200MG	A090607	004	Jan 13, 2011	Apr	CAHN
	AB		200MG	A090607	004	Jan 13, 2011	Jan	NEWA
>A>	AB	ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Apr	CAHN
>A>	AB		100MG	A090607	002	Jan 13, 2011	Apr	CAHN
>A>	AB		150MG	A090607	003	Jan 13, 2011	Apr	CAHN
>A>	AB		200MG	A090607	004	Jan 13, 2011	Apr	CAHN
>A>	AB	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	Apr	NEWA
>A>	AB		100MG	A078134	002	Apr 19, 2011	Apr	NEWA
>A>	AB		150MG	A078134	003	Apr 19, 2011	Apr	NEWA
>A>	AB		200MG	A078134	004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB		JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
AB			25MG	A200220	002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT		ALCON RES	0.005%	A091449	001	Mar 22, 2011	Mar	NEWA
AT		APOTEX	0.005%	A077697	001	Mar 22, 2011	Mar	NEWA
AT		BAUSCH AND LOMB	0.005%	A201006	001	Mar 22, 2011	Mar	NEWA
AT		MYLAN	0.005%	A201786	001	Mar 22, 2011	Mar	NEWA
AT		PHARMAFORCE	0.005%	A200925	001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+	PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

>D>	AP	GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC
>A>		@	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
	AB		500MG	A090843	002	Feb 14, 2011	Jan	NEWA
	AB		750MG	A090843	003	Feb 14, 2011	Jan	NEWA
	AB		1GM	A090843	004	Feb 14, 2011	Jan	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	AB	DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011	Feb	NEWA
	AB	GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

	AT	HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

>A>	+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	Apr	NEWA
>A>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	Apr	NEWA

LEVONORGESTREL

TABLET; ORAL

PLAN B

	@	TEVA WOMENS	0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN
AB	+		0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

	@	VALEANT PHARM INTL	2MG	N008720	001	Dec 19, 1991	Mar	DISC

LEVORPHANOL TARTRATE

		ROXANE	2MG	A074278	001	Mar 31, 2000	Mar	CTEC

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVO-T

AB1, AB2, AB3		ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC

TABLET; ORAL
LEVO-T

AB1, AB2, AB3		ALARA PHARM	0.075MG	N021342	003	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.088MG	N021342	004	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.1MG	N021342	005	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.112MG	N021342	006	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.125MG	N021342	007	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.137MG	N021342	012	Dec 08, 2003	Feb	CTEC
AB1, AB2, AB3			0.15MG	N021342	008	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.175MG	N021342	009	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.2MG	N021342	010	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3	+		0.3MG	N021342	011	Mar 01, 2002	Feb	CTEC

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
LIDOCAINE HYDROCHLORIDE

AT		HI TECH PHARMA	2%	A040837	001	Mar 23, 2011	Mar	NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

AB		GLENMARK GENERICS	450MG	A091616	001	Feb 14, 2011	Jan	NEWA

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

>D>	AB	ALEMBIC LTD	25MG	A090428	001	Oct 06, 2010	Apr	CAHN
>D>	AB		100MG	A090428	003	Oct 06, 2010	Apr	CAHN
>A>	AB	ALEMBIC PHARMS LTD	25MG	A090428	001	Oct 06, 2010	Apr	CAHN
>A>	AB		50MG	A090428	002	Oct 06, 2010	Apr	NEWA
>A>	AB		50MG	A090428	002	Oct 06, 2010	Apr	NEWA
>A>	AB		100MG	A090428	003	Oct 06, 2010	Apr	CAHN
	AB	MYLAN	25MG	A091590	001	Oct 06, 2010	Jan	NEWA
	AB		50MG	A091590	002	Oct 06, 2010	Jan	NEWA
	AB		100MG	A091590	003	Oct 06, 2010	Jan	NEWA

LOTEPREDNOL ETABONATE

>A> OINTMENT; OPHTHALMIC
>A> LOTEMAX

>A>	+	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011	Apr	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Feb	NEWA
AA			25MG	A201451	002	Feb 23, 2011	Feb	NEWA
AA			50MG	A201451	003	Feb 23, 2011	Feb	NEWA
AA		JUBILANT CADISTA	12.5MG	A040659	001	Jun 04, 2010	Jan	CAHN
AA			25MG	A040659	002	Jun 04, 2010	Jan	CAHN

MELOXICAM

TABLET; ORAL
MELOXICAM

AB		MYLAN	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN
AB			15MG	A077934	002	Jul 20, 2006	Feb	CAHN

MEROPENEM

INJECTABLE; INJECTION
MEROPENEM

AP		SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Mar	NEWA
AP			1GM/VIAL	A091201	002	Mar 29, 2011	Mar	NEWA

MERREM

AP	+	ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Mar	CTNA
AP	+		1GM/VIAL	N050706	001	Jun 21, 1996	Mar	CTNA

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

AB		MYLAN	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
AB			850MG	A075973	002	Jan 25, 2002	Feb	CAHN
AB			1GM	A075973	003	Jan 25, 2002	Feb	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOPLUS MET

AB		TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
AB	+		850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Feb	NEWA
AB			850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Feb	NEWA

METHYLERGONOVINE MALEATE

TABLET; ORAL
METHERGINE

>D>	+	NOVARTIS	0.2MG	N006035	003		Apr	CTEC
>A> AB	+		0.2MG	N006035	003		Apr	CTEC

>A> METHYLERGONOVINE MALEATE

>A> AB		NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr	NEWA

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189	001	Oct 31, 1997	Jan	CAHN
AB			8MG	A040189	002	Oct 31, 1997	Jan	CAHN
AB			16MG	A040189	003	Jul 20, 2007	Jan	CAHN
AB			32MG	A040189	004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

>A>	AP	HEMOFARM	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
>A>	AP		EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
>D>	AP	HEMOPHARM USA	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
>D>	AP		EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
		@ HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC
		@	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

	AB	G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan	NEWA

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

	+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan	CRLD

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDOZALAM HYDROCHLORIDE

>A>	AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	NEWA
>A>	AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

		@ HOSPIRA	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

	AB	ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jan	NEWA
	AB		30MG	A077959	002	Feb 14, 2011	Jan	NEWA
	AB		45MG	A077959	003	Feb 14, 2011	Jan	NEWA

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR

NABUMETONE

TABLET; ORAL

NABUMETONE

	AB	LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
	AB		750MG	A090445	002	Jan 12, 2011	Jan	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

>A>	AP	IBI	EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Apr	NEWA
>D>		+ SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Apr	CTEC

INJECTABLE; INJECTION
NAFCILLIN SODIUM

>A>	AP	+	SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HYDROCHLORIDE

	AB		ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL
NAPROXEN

	AB		MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA
	AB			375MG	A091416	002	Feb 14, 2011	Jan	NEWA
	AB			500MG	A091416	003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL
NARATRIPTAN

>A>	AB		APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Apr	NEWA
>A>	AB			EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Apr	NEWA
	AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
NARATRIPTAN

	AB		INDICUS PHARMA	EQ 1MG BASE	A200502	001	Feb 28, 2011	Feb	NEWA
	AB			EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL
NATEGLINIDE

	AB		WATSON LABS	60MG	A077462	001	Mar 30, 2011	Mar	NEWA
	AB			120MG	A077462	002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL
VIRAMUNE XR

		+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

>D>	AB1		BIOVAIL	30MG	A075269	001	Dec 04, 2000	Apr	CAHN
>D>	AB2			30MG	A075289	002	Feb 06, 2001	Apr	CAHN
>D>	AB2			60MG	A075289	001	Sep 27, 2000	Apr	CAHN
>D>	AB1			60MG	A075269	002	Dec 04, 2000	Apr	CAHN
>D>	AB1			90MG	A076070	001	Aug 16, 2002	Apr	CAHN
>A>	AB1		VALEANT INTL	30MG	A075269	001	Dec 04, 2000	Apr	CAHN
>A>	AB2			30MG	A075289	002	Feb 06, 2001	Apr	CAHN
>A>	AB2			60MG	A075289	001	Sep 27, 2000	Apr	CAHN
>A>	AB1			60MG	A075269	002	Dec 04, 2000	Apr	CAHN
>A>	AB1			90MG	A076070	001	Aug 16, 2002	Apr	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB		MYLAN	8.5MG	A091001	001	Jan 26, 2011	Jan	NEWA
AB			17MG	A091001	002	Jan 26, 2011	Jan	NEWA
AB			25.5MG	A091001	003	Jan 26, 2011	Jan	NEWA
AB			34MG	A091001	004	Jan 26, 2011	Jan	NEWA

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356	007	Jan 02, 2008	Jan	CFTG
AB			25.5MG	N020356	006	Jan 02, 2008	Jan	CFTG
AB	+		34MG	N020356	005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

>A>	AB	+	SHIONOGI INC	25MG/5ML	N009175	001		Apr	CFTG
>D>		+	SHIONOGI PHARMA	25MG/5ML	N009175	001		Apr	CFTG

NITROFURANTOIN

>A>	AB	AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Apr	NEWA

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB		MYLAN	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934	002	Jul 09, 2002	Feb	CAHN

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA		VISTAPHARM	100,000 UNITS/ML	A065422	001	Mar 07, 2011	Feb	NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

>A>	AP	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Apr	NEWA
>A>	AP		EQ 1MG BASE/ML	A090986	002	May 11, 2011	Apr	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Jan	NEWA
AP			EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Jan	NEWA
AP			EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Jan	NEWA
>A>	AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Apr	NEWA
>A>	AP		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Apr	NEWA
>A>	AP		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Apr	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB		RANBAXY	4MG	A078602	001	Feb 24, 2011	Feb	NEWA
AB			8MG	A078602	002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP		TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Jan	CMFD

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Apr	CRLD
>A>	AP	+	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Apr	CRLD

SOLUTION; ORAL
ONDANSETRON HYDROCHLORIDE

	AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483	001	Jan 31, 2011	Jan	NEWA
	AA	SILARX	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jan	NEWA

TABLET; ORAL
ONDANSERTRON HYDROCHLORIDE

	AB	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Mar	NEWA
	AB		EQ 8MG BASE	A077729	002	Mar 28, 2011	Mar	NEWA
	AB		EQ 24MG BASE	A077729	003	Mar 28, 2011	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)
OXALIPLATIN

	AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Jan	NEWA
>A>	AP		50MG/VIAL	A090849	001	Apr 28, 2011	Apr	NEWA
>A>	AP		100MG/VIAL	A090849	002	Apr 28, 2011	Apr	NEWA
	AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN

	AB	MYLAN	600MG	A075847	001	Feb 28, 2001	Feb	CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

	AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb	NEWA
	AB		15MG	A091313	002	Feb 18, 2011	Feb	NEWA
	AB		30MG	A091313	003	Feb 18, 2011	Feb	NEWA
	AB	RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb	NEWA
	AB		10MG	A091490	002	Mar 09, 2011	Feb	NEWA
	AB		15MG	A091490	003	Mar 09, 2011	Feb	NEWA
	AB		20MG	A091490	004	Mar 09, 2011	Feb	NEWA
	AB		30MG	A091490	005	Mar 09, 2011	Feb	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL
OXYMORPHONE HYDROCHLORIDE

	AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan	NEWA
	AB		10MG	A091443	001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

		@ ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
		@	15MG	N021610	006	Feb 29, 2008	Feb	DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

	AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Jan	NEWA
	AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619	001	Jan 19, 2011	Jan	NEWA
	AB		EQ 40MG BASE	A077619	002	Jan 19, 2011	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB	KUDCO IRELAND	EQ 20MG BASE	A078281	001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970	002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074	002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231	002	Jan 19, 2011	Jan	NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PAROXETINE HYDROCHLORIDE

>A> AB	MYLAN	EQ 37.5MG BASE	A091427	001	Apr 14, 2011	Apr	NEWA

PAXIL CR

>D> +	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Apr	CTEC
>A> AB +		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

>D> AB	BIOVAIL	400MG	A075028	001	Jul 20, 1998	Apr	CAHN
>A> AB	VALEANT INTL	400MG	A075028	001	Jul 20, 1998	Apr	CAHN

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL
PHENTERMINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	37.5MG	A200272	001	Jan 31, 2011	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
PIPERACILLIN AND TAZOBACTAM

AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN

PIROXICAM

CAPSULE; ORAL
PIROXICAM

@	MYLAN	10MG	A074043	001	Sep 22, 1992	Feb	CAHN
@		20MG	A074043	002	Sep 22, 1992	Feb	CAHN

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN
AB		5MG	A040362	002	Aug 29, 2001	Jan	CAHN
AB		10MG	A040362	001	Aug 29, 2001	Jan	CAHN
AB		20MG	A040362	003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268	001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268	002	Feb 27, 1998	Jan	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927	002		Jan	CMFD

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON

@	XANODYNE PHARM	65MG	N010997	003		Jan	DISC

PROPOXYPHENE HYDROCHLORIDE

@	TEVA	65MG	A088615	001	Oct 22, 1984	Mar	DISC
@	VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009	Mar	DISC
@	WEST WARD	65MG	A083501	001		Jan	DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVON-N

@	XANODYNE PHARM	100MG	N016862	002		Jan	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	60MG	A090321	001	Mar 25, 2011	Mar	NEWA
AB		80MG	A090321	002	Mar 25, 2011	Mar	NEWA
AB		120MG	A090321	003	Mar 25, 2011	Mar	NEWA
AB		160MG	A090321	004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213	005	Apr 08, 2011	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

AB	MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE	A076036	002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE	A076036	003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE	A076036	004	Jan 28, 2005	Feb	CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HYDROCHLORIDE

@	MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000	Feb	CAHN
@		EQ 300MG BASE	A075564	002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011	Mar	NEWA

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023	001	Aug 22, 1997	Feb	CAHN

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 300MG BASE	A074023	002	Aug 22, 1997	Feb	CAHN

RIFAXIMIN

TABLET; ORAL
XIFAXAN

+	SALIX PHARMS	550MG	N022554	001	Mar 24, 2010	Feb	CRLD

RISPERIDONE

SOLUTION; ORAL
RISPERIDONE

AA	TARO	1MG/ML	A090347	001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL
RISPERIDONE

@	RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010	Feb	DISC
@		0.5MG	A077784	002	Jun 08, 2010	Feb	DISC
@		1MG	A077784	003	Jun 08, 2010	Feb	DISC
@		2MG	A077784	004	Jun 08, 2010	Feb	DISC
@		3MG	A077784	005	Jun 08, 2010	Feb	DISC
@		4MG	A077784	006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

AB	MYLAN	0.5MG	A091537	001	Mar 30, 2011	Mar	NEWA
AB		1MG	A091537	002	Mar 30, 2011	Mar	NEWA
AB		2MG	A091537	003	Mar 30, 2011	Mar	NEWA
AB		3MG	A091537	004	Mar 30, 2011	Mar	NEWA
AB		4MG	A091537	005	Mar 30, 2011	Mar	NEWA
>A> AB	WATSON LABS FLORIDA	0.5MG	A076996	001	Apr 19, 2011	Apr	NEWA
>A> AB		1MG	A076996	002	Apr 19, 2011	Apr	NEWA
>A> AB		2MG	A076996	003	Apr 19, 2011	Apr	NEWA
>A> AB		3MG	A076996	004	Apr 19, 2011	Apr	NEWA
>A> AB		4MG	A076996	005	Apr 19, 2011	Apr	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Jan	CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Jan	CAHN

ROFLUMILAST

TABLET; ORAL
DALIRESP

+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011	Feb	NEWA

RUFINAMIDE

SUSPENSION; ORAL
BANZEL

+	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Mar	NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECONAL SODIUM

+	MARATHON PHARMS	50MG	A086101	001	Oct 03, 1983	Jan	CAHN
+		100MG	A086101	002	Oct 03, 1983	Jan	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
SERTRALINE HYDROCHLORIDE

		@ ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	DISC

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

>D>	AB	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
>A>		@	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
>D>	AB		EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
>A>		@	EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
>D>	AB		EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
>A>		@	EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
	AB	MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
	AB		EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
	AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
		@ ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
		@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
		@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION
FERRLECIT

	AB	+ SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999	Mar	CFTG

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

	AB	GENERAMEDIX	62.5MG/5ML	A078215	001	Mar 31, 2011	Mar	NEWA

>D> SODIUM FLUORIDE F-18

>D> INJECTABLE; INTRAVENOUS
>D> SODIUM FLUORIDE F 18

>D>		+ NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Apr	DISC
>A>		@	10-200mCi/ML	N022494	001	Jan 26, 2011	Apr	DISC
		+	10-200mCi/ML	N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS
NITHIODOTE

		+ HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA

SODIUM NITRITE

		+ HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Jan	NEWA

SPINOSAD

SUSPENSION; TOPICAL
NATROBA

		+ PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA

SUMATRIPTAN SUCCINATE

TABLET; ORAL
SUMATRIPTAN SUCCINATE

		@ ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009	Mar	DISC
		@	EQ 50MG BASE	A078241	002	Aug 10, 2009	Mar	DISC
		@	EQ 100MG BASE	A078241	003	Aug 10, 2009	Mar	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB		JUBILANT CADISTA	EQ 1MG BASE	A075317	001	Dec 20, 2004	Jan	CAHN
AB			EQ 2MG BASE	A075317	002	Dec 20, 2004	Jan	CAHN
AB			EQ 5MG BASE	A075317	003	Dec 20, 2004	Jan	CAHN
AB			EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

AB		MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN
	@	ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

AB	+	IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD

TESTOSTERONE

GEL, METERED; TRANSDERMAL
ANDROGEL

>A>	+	ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Apr	NEWA

FORTESTA

	+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar	CPOT

THEOPHYLLINE

SOLUTION; ORAL
THEOPHYLLINE

	+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Mar	NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

AB		MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

AT		FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Mar	CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

AP		DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb	NEWA
AP		SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS
TOPOTECAN

AP		HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb	NEWA
		SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199	001	Feb 25, 2011	Feb	NEWA
			EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199	002	Feb 25, 2011	Feb	NEWA
AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199	003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB	VINTAGE PHARMS	5MG	A090613	001	Mar 22, 2011	Mar	NEWA
AB		10MG	A090613	002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613	003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613	004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP	PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA

TRIMIPRAMINE MALEATE

CAPSULE; ORAL
TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

>A> VANDETANIB

>A> TABLET; ORAL
>A> VANDETANIB

>A>	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Apr	NEWA
>A> +		300MG	N022405	002	Apr 06, 2011	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011	Apr	NEWA
>A> AB		EQ 75MG BASE	A200834	002	Apr 14, 2011	Apr	NEWA
>A> AB		EQ 150MG BASE	A200834	003	Apr 14, 2011	Apr	NEWA
>A> AB	BIOVAIL LABS INTL	EQ 75MG BASE	A090071	002	Apr 15, 2011	Apr	NEWA
>A> AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Apr	NEWA
>A> AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011	Apr	NEWA
>A> AB		EQ 75MG BASE	A078421	002	May 06, 2011	Apr	NEWA
>A> AB		EQ 150MG BASE	A078421	003	May 06, 2011	Apr	NEWA
>A> AB	WOCKHARDT	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Apr	NEWA
>A> AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Apr	NEWA
>A> AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Apr	NEWA
>A> AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174	001	Apr 14, 2011	Apr	NEWA
>A> AB		EQ 75MG BASE	A090174	002	Apr 14, 2011	Apr	NEWA

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	EQ 150MG BASE	A090174	003	Apr 14, 2011	Apr	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VIIBRYD

		TROVIS PHARMS	10MG	N022567	001	Jan 21, 2011	Jan	NEWA
			20MG	N022567	002	Jan 21, 2011	Jan	NEWA
	+		40MG	N022567	003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

		@ APP PHARMS	1MG/ML	A076401	001	Oct 28, 2003	Jan	DISC

ZIDOVUDINE

INJECTABLE; INJECTION
ZIDOVUDINE

	AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN

TABLET; ORAL
ZIDOVUDINE

		@ MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Feb	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

	AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
	AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
ZOLPIDEM TARTRATE

>A>	AB	ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	Apr	NEWA
>A>	AB	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>		SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>		SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

>A>	+	CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
>D>	+	CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN

CHLORAPREP SINGLE SWABSTICK

>A>	+	CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
>D>	+	CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN

CHLORAPREP TRIPLE SWABSTICK

>A>	+	CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

		MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

	+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

	+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

	+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

	+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA

TABLET; ORAL

ALLEGRA ALLERGY

		SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
	+		180MG	N020872	010	Jan 24, 2011	Jan	NEWA

ALLEGRA HIVES

		SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
	+		180MG	N020872	009	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA ALLERGY

		SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

		SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

		DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
		TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

		DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
		TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

		DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA

TABLET; ORAL
FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	180MG	A076502	008	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447	006	Apr 13, 2011	Mar	NEWA
	180MG	A076447	008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011	Mar	NEWA
	180MG	A076502	009	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447	007	Apr 13, 2011	Mar	NEWA
	180MG	A076447	009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011	Jan	NEWA

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011	Jan	NEWA

IBUPROFEN

TABLET; ORAL
IBUPROFEN

MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	Jan	NEWA
	200MG	A091239	001	Feb 01, 2011	Jan	NEWA
MERRO PHARM	200MG	A070985	001	Oct 02, 1987	Jan	CAHN
SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	Mar	NEWA
	200MG	A091355	001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION
NOVOLIN N

+ NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991	Jan	CRLD

LEVONORGESTREL

TABLET; ORAL
PLAN B

+ TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

MINOXIDIL

AEROSOL, FOAM; TOPICAL
MINOXIDIL

>A> PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011	Apr	NEWA

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011	Feb	NEWA

POTASSIUM IODIDE

TABLET; ORAL
IOSAT

>A> ANBEX	65MG	N018664	002	May 12, 2011	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Feb	CAHN
>A>	PERRIGO R AND D	EQ 150MG BASE	A091429	002	May 11, 2011	Apr	NEWA
>A>		EQ 150MG BASE	A091429	001	May 11, 2011	Apr	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2011

NO APRIL 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE - ZYTIGA						
N202379 001					**>A>** NCE	Apr 28, 2016
ADAPALENE - DIFFERIN						
N021753 001	7868044	Mar 12, 2023	U-1078			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 001					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 002					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 003					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO						
N022545 004					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALVIMOPAN - ENTEREG						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE						
A078381 005					PC	Jul 02, 2011
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE						
A078381 006					PC	Jul 02, 2011
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
ARIPIPRAZOLE - ABILIFY						
N021436 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 004					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 005					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 006					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021713 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021866 001					I-633	Feb 16, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 001					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 002					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 003					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 004					D-130	Feb 04, 2014
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN MEDOXOMIL - EDARBI							
N200796	002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
		5736555	Jun 25, 2012	DS DP U-3			
		5958961	Jun 06, 2014	DP U-3			
		7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
AZITHROMYCIN - ZMAX							
N050797	001	7887844	Feb 14, 2024	DP			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N021929	002	7897646	Sep 09, 2018	U-1118			
CELECOXIB - CELEBREX							
N020998	001	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX							
N020998	002	5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX							
N020998	003	5760068	Jun 02, 2015	U-672			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS							
N021441	001	**>A>** 7863287	Feb 28, 2027	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688	001					I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688	002					I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688	003					I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						ODE	Feb 25, 2018
CLOPIDOGREL BISULFATE - PLAVIX							
N020839	001	4847265	Nov 17, 2011	DS DP			
		4847265*PED	May 17, 2012				
		5576328	Jan 31, 2014	U-432	Y		
		5576328*PED	Jul 31, 2014				
		6429210	Jun 10, 2019	DS DP			
		6429210*PED	Dec 10, 2019				
		6504030	Jun 10, 2019	DS			
		6504030*PED	Dec 10, 2019				
CLOPIDOGREL BISULFATE - PLAVIX							
N020839	002	4847265	Nov 17, 2011	DS DP			
		4847265*PED	May 17, 2012				
		6429210	Jun 10, 2019	DS DP			
		6429210*PED	Dec 10, 2019				
		6504030	Jun 10, 2019	DS			
		6504030*PED	Dec 10, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLCHICINE - COLCRYS							
N022352 001		7906519	Feb 17, 2029	U-1116			
		7915269	Feb 17, 2029	U-1007			
DESIRUDIN RECOMBINANT - IPRIVASK							
N021271 001		6103515	Aug 15, 2017	DS			
DICLOFENAC POTASSIUM - ZIPSOR							
N022202 001		7884095	Feb 24, 2029	U-1111			
		7884095*PED	Aug 24, 2029				
DICLOFENAC SODIUM - SOLARAZE							
N021005 001	**>A>**	5929048	Jun 17, 2014	U-402			
	>A>	5985850	Aug 11, 2015	DP			
DIENOGEST; ESTRADIOL VALERATE - NATAZIA							
N022252 001		6133251	Oct 25, 2016	DP U-828	Y		
		6133251	Oct 25, 2016	DP U-112	Y		
		6133251	Oct 25, 2016	DP U-1	Y		
		6884793	Oct 25, 2016	DP	Y		
DORIPENEM - DORIBAX							
N022106 001		5317016	Jun 05, 2015	DS DP U-282			
DORIPENEM - DORIBAX							
N022106 002		5317016	Jun 05, 2015	DS DP U-282			
DOXEPIN HYDROCHLORIDE - SILENOR							
N022036 001		7915307	Aug 24, 2027	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR							
N022036 002		7915307	Aug 24, 2027	U-620			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL							
N022574 001		5798338	Jul 10, 2015	DP			
		6441168	Apr 17, 2020	DS			
		6958326	Dec 20, 2021	DP			
		7163931	Mar 03, 2022	U-1			
ELTROMBOPAG OLAMINE - PROMACTA							
N022291 001	**>A>**	7547719	Jul 13, 2025	DS DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA							
N022291 002	**>A>**	7547719	Jul 13, 2025	DS DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA							
N022291 003	**>A>**	7547719	Jul 13, 2025	DS DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
ETRAVIRINE - INTELENCE						
N022187 001	7887845	Mar 25, 2019	DP			
ETRAVIRINE - INTELENCE						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Nov 05, 2019	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
EVEROLIMUS - AFINITOR						
N022334 001					ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR						
N022334 002					ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR						
N022334 003					NCE	Mar 30, 2014
					ODE	Oct 29, 2017
EXENATIDE SYNTHETIC - BYETTA						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYETTA						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
FAMCICLOVIR - FAMVIR						
N020363 001					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR						
N020363 002					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR						
N020363 003					M-98	Jan 31, 2014
FAMOTIDINE; IBUPROFEN - DUEXIS						
N022519 001					>A> NC	Apr 23, 2014
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 003	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
FENOFIBRIC ACID - FIBRICOR						
N022418 001	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
FENOFIBRIC ACID - FIBRICOR						
N022418 002	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
FENTANYL CITRATE - ABSTRAL						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - ABSTRAL							
N022510 006		6759059	Sep 24, 2019	DP U-767			
		6761910	Sep 24, 2019	DP U-767			
		7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - FENTORA							
N021947 001	**>A>**	7862832	Jun 15, 2028	DP			
	>A>	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA							
N021947 002	**>A>**	7862832	Jun 15, 2028	DP			
	>A>	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA							
N021947 003	**>A>**	7862832	Jun 15, 2028	DP			
	>A>	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA							
N021947 004	**>A>**	7862832	Jun 15, 2028	DP			
	>A>	7862833	Jun 15, 2028	DP			
FERUMOXYTOL - FERAHEME							
N022180 001		7871597	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ							
N022030 001		7855230	May 11, 2019	U-913			
FESOTERODINE FUMARATE - TOVIAZ							
N022030 002		7855230	May 11, 2019	U-913			
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
A079043 001						PC	Jul 27, 2011
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA							
N021112 001		7915243	Mar 22, 2026	DP			
FULVESTRANT - FASLODEX							
N021344 001		6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
		6774122*PED	Jul 09, 2021			PED	Mar 09, 2014
		7456160	Jan 09, 2021	U-596			
		7456160*PED	Jul 09, 2021				
GABAPENTIN - GABAPENTIN							
A078974 001						PC	Aug 22, 2011
GABAPENTIN - GRALISE							
N022544 001		6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
		6488962	Jun 20, 2020	DP			
		6635280	Sep 19, 2016	DP			
		6723340	Oct 25, 2021	DP			
		7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN - GRALISE							
N022544 002		6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
		6488962	Jun 20, 2020	DP			
		6635280	Sep 19, 2016	DP			
		6723340	Oct 25, 2021	DP			
		7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			
GABAPENTIN ENACARBIL - HORIZANT							
N022399 001	**>A>**	6818787	Nov 06, 2022	DS DP		**>A>** NCE	Apr 06, 2016
GADOBUTROL - GADAVIST							
N201277 001		5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST							
N201277 002		5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST							
N201277 003		5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST							
N201277 004		5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST							
N201277 005		5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOFOSVESET TRISODIUM - ABLAVAR							
N021711 001		5362475	Nov 08, 2011	DS			
		6676929	May 26, 2015	DP			
		7011815	Feb 01, 2015	U-1112			
		7060250	May 26, 2015	DS			
		7229606	May 26, 2015	U-1112			
GADOFOSVESET TRISODIUM - ABLAVAR							
N021711 002		5362475	Nov 08, 2011	DS			
		6676929	May 26, 2015	DP			
		7011815	Feb 01, 2015	U-1112			
		7060250	May 26, 2015	DS			
		7229606	May 26, 2015	U-1112			
GEMCITABINE HYDROCHLORIDE - GEMCITABINE							
A079183 001						PC	May 14, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE							
A077983 001						PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE							
A077983 002						PC	Jul 24, 2011
GRANISETRON HYDROCHLORIDE - KYTRIL							
N020239 001						**>A>** M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL							
N020239 002						**>A>** M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL							
N020239 003						**>A>** M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL							
N020239 004						**>A>** M-102	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 001					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 002					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 003					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 004					I-635	Feb 25, 2014
HYDROXOCOBALAMIN - CYANOKIT						
N022041 001	**>A>** 5834448	Nov 14, 2016	DP		**>A>** ODE	Dec 15, 2013
HYDROXYPROGESTERONE CAPROATE - MAKENA						
N021945 001					ODE	Feb 03, 2018
IMIQUIMOD - ZYCLARA						
N022483 001					I-636	Mar 24, 2014
INSULIN GLARGINE RECOMBINANT - LANTUS						
N021081 001	**>A>** 7918833	Sep 23, 2027	DP			
	>A> 7918833*PED	Mar 23, 2028				
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N021629 003	**>A>** 7918833	Sep 23, 2027	DP			
INSULIN RECOMBINANT HUMAN - HUMULIN R						
N018780 001					NR	Mar 25, 2014
INSULIN RECOMBINANT HUMAN - HUMULIN R PEN						
N018780 005					NR	Mar 25, 2014
IOFLUPANE I-123 - DATSCAN						
N022454 001					NCE	Jan 14, 2016
IXABEPILONE - IXEMPRA KIT						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
LAMOTRIGINE - LAMICTAL ODT						
N022251 001	**>A>** 7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 002	**>A>** 7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 003	**>A>** 7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 004	**>A>** 7919115	Jan 04, 2029	DS DP			
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANSOPRAZOLE - PREVACID						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LANSOPRAZOLE - PREVACID						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LENALIDOMIDE - REVLIMID						
N021880 001	7855217	Nov 24, 2024	DS DP			
LENALIDOMIDE - REVLIMID						
N021880 002	7855217	Nov 24, 2024	DS DP			
LENALIDOMIDE - REVLIMID						
N021880 004	7855217	Nov 24, 2024	DS DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 002	**>A>** 6500829	Dec 31, 2019	DS DP		**>A>** ODE	Mar 07, 2015
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 003	**>A>** 6500829	Dec 31, 2019	DS DP		**>A>** ODE	Mar 07, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOTEPREDNOL ETABONATE - LOTEMAX						
N200738 001					**>A>** NDF	Apr 15, 2014
					>A> PED	Oct 15, 2014
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 001	7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 002	7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N022024 001	**>A>** 7919116	Mar 20, 2018	U-973			
	>A> 7919116	Mar 20, 2018	U-1120			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N022024 002	**>A>** 7919116	Mar 20, 2018	U-973			
	>A> 7919116	Mar 20, 2018	U-1120			
METRONIDAZOLE - VANDAZOLE						
N021806 001	7456207	Sep 22, 2024	DP			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 001	7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 002	7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 003	7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 004	7888342	Nov 05, 2021	U-882			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 001	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 002	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 003	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 004	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 005	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 006	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 007	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 008	7919483	Feb 28, 2027	U-1078			
MOMETASONE FUROATE MONOHYDRATE - NASONEX						
N020762 001					M-99	Jan 19, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N022428 001	**>A>** 7671070*PED	Mar 29, 2020				
MUPIROCIN CALCIUM - BACTROBAN						
N050746 001	**>A>** 6025389	Oct 20, 2014	DP U-1122			
NEVIRAPINE - VIRAMUNE XR						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021246 001	5763483	Dec 27, 2016	DS U-376			
	5763483	Dec 27, 2016	DS U-1113			
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
PACLITAXEL - ABRAXANE						
N021660 001	**>A>** 7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
PALIPERIDONE - INVEGA						
N021999 001					**>A>** NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 002					**>A>** NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 003					**>A>** NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 004					**>A>** NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 006					**>A>** NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE						
A091427 001					**>A>** PC	Nov 01, 2011
PEMETREXED DISODIUM - ALIMTA						
N021462 001					M-61	Mar 17, 2014
					PED	Sep 17, 2014
PEMETREXED DISODIUM - ALIMTA						
N021462 002					M-61	Mar 17, 2014
					PED	Sep 17, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERFLUTREN - DEFINITY							
N021064 001		5527521	Feb 22, 2015	DP U-665			
		5585112	Dec 17, 2013	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684 001	**>A>**	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684 002	**>A>**	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684 003	**>A>**	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N050684 004	**>A>**	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N050750 001	**>A>**	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N050750 002	**>A>**	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N050750 003	**>A>**	7915229	Apr 14, 2023	DP			
PLERIXAFOR - MOZOBIL							
N022311 001		7897590	Jul 22, 2023			U-936	
		RE42152	Dec 10, 2013	DP			
RALTEGRAVIR POTASSIUM - ISENTRESS							
N022145 001		7169780	Oct 03, 2023	DS DP			
RANOLAZINE - RANEXA							
N021526 001		6369062	May 27, 2019	DP	Y		
RETAPAMULIN - ALTABAX							
N022055 001		7875630	Feb 14, 2027	DS			
		RE39128	Apr 12, 2021	DS DP		U-805	
RIFAXIMIN - XIFAXAN							
N021361 001		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
	>A>	7928115	Jul 24, 2029			U-1121	
RIFAXIMIN - XIFAXAN							
N022554 001		7612199	Jun 19, 2024	DS DP			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
RIZATRIPTAN BENZOATE - MAXALT							
N020864 001		5602162	Feb 11, 2014		Y		
RIZATRIPTAN BENZOATE - MAXALT							
N020864 002		5602162	Feb 11, 2014		Y		
RIZATRIPTAN BENZOATE - MAXALT-MLT							
N020865 001		5602162	Feb 11, 2014		Y	U-240	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIZATRIPTAN BENZOATE - MAXALT-MLT							
N020865 002		5602162	Feb 11, 2014	U-240	Y		
ROFLUMILAST - DALIRESP							
N022522 001		5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
ROTIGOTINE - NEUPRO							
N021829 001	**>A>**	6699498	Nov 27, 2020	DP			
ROTIGOTINE - NEUPRO							
N021829 002	**>A>**	6699498	Nov 27, 2020	DP			
ROTIGOTINE - NEUPRO							
N021829 003	**>A>**	6699498	Nov 27, 2020	DP			
RUFINAMIDE - BANZEL							
N201367 001		6740669	Aug 17, 2020	DS DP		NCE	Nov 14, 2013
						ODE	Nov 14, 2015
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE							
N201444 001						ODE	Jan 14, 2018
SODIUM OXYBATE - XYREM							
N021196 001		7668730	Jun 16, 2024	U-1110			
		7895059	Dec 17, 2022	U-1110			
SORAFENIB TOSYLATE - NEXAVAR							
N021923 001		7897623	Jan 12, 2020	DP			
SPINOSAD - NATROBA							
N022408 001		5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
		6063771	Jun 22, 2019	DP U-1105			
		6342482	Jun 22, 2019	DP U-1105			
		7030095	Jul 02, 2021	DP U-1105			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO							
N022239 001		7776007	Apr 09, 2025	DP			
		7901385	Jul 31, 2026	DP			
TELBIVUDINE - TYZEKA							
N022011 001		7858594	Sep 11, 2023	DS DP U-999			
TESTOSTERONE - ANDROGEL							
N022309 001						**>A>** NP	Apr 29, 2014
TESTOSTERONE - FORTESTA							
N021463 001	**>A>**	6319913	Nov 09, 2018	U-490			
	>A>	6579865	Nov 09, 2018	DP			
THALIDOMIDE - THALOMID							
N020785 001		7874984	Aug 28, 2018	U-733			
		7874984	Aug 28, 2018	U-732			
		7874984	Aug 28, 2018	U-442			
		7874984	Aug 28, 2018	U-371			
		7874984	Aug 28, 2018	U-1109			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
THALIDOMIDE - THALOMID						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
TIGECYCLINE - TYGACIL						
N021821 001	7879828	Feb 05, 2029	DP			
VANDETANIB - VANDETANIB						
N022405 001	**>A>** 6414148	Sep 23, 2017	DS		**>A>** NCE	Apr 06, 2016
	>A> 7173038	Aug 14, 2021	DS DP		**>A>** ODE	Apr 06, 2018
VANDETANIB - VANDETANIB						
N022405 002	**>A>** 6414148	Sep 23, 2017	DS		**>A>** NCE	Apr 06, 2016
	>A> 7173038	Aug 14, 2021	DS DP		**>A>** ODE	Apr 06, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm